CSF1R Inhibitors for Parkinson's Disease

📖 Wiki Page

therapeutic3030 wordssynced 2026-04-02

CSF1R Inhibitors for Parkinson's Disease

Overview

...

CSF1R Inhibitors for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CSF1R Inhibitors for Parkinson's Disease</th> PMID: 39719687
</tr>
<tr>
<td class="label">Gene</td>
<td>CSF1R, chromosome 5q32</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>972 amino acids</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~165 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Ligands</td>
<td>CSF1 (M-CSF), IL-34</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">RAS/RAF/MEK/ERK</td>
<td>Proliferation, survival</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Survival, metabolism</td>
</tr>
<tr>
<td class="label">PLCγ</td>
<td>Calcium signaling</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>Transcription activation</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Inflammatory gene expression</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Plexxikon/CarThera</td>
</tr>
<tr>
<td class="label">PLX3397 (Pexidartinib)</td>
<td>Plexxikon/Daiichi Sankyo</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">JNJ-5277630</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Cabiralizumab</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Relevance</td>
</tr>
<tr>
<td class="label">Microglial depletion</td>
<td>Reversible upon drug withdrawal</td>
</tr>
<tr>
<td class="label">No neuronal loss</td>
<td>Microglia not required for neuronal survival</td>
</tr>
<tr>
<td class="label">Normal brain development</td>
<td>Developmental milestones unaffected</td>
</tr>
<tr>
<td class="label">Peripheral immune intact</td>
<td>Blood monocytes remain functional</td>
</tr>
<tr>
<td class="label">No increased infection</td>
<td>Baseline immune surveillance maintained</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">TSPO PET</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">[11C]CPPC PET</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">CarThera</td>
<td>PLX5622</td>
</tr>
<tr>
<td class="label">Daiichi Sankyo</td>
<td>PLX3397</td>
</tr>
<tr>
<td class="label">Novartis</td>
<td>BLZ945</td>
</tr>
<tr>
<td class="label">Janssen</td>
<td>JNJ-5277630</td>
</tr>
<tr>
<td class="label">BMS</td>
<td>Cabiralizumab</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CSF1R inhibitors</td>
<td>Reduce microglial numbers</td>
</tr>
<tr>
<td class="label">TREM2 agonists</td>
<td>Enhance phagocytosis</td>
</tr>
<tr>
<td class="label">NLRP3 inhibitors</td>
<td>Block inflammasome</td>
</tr>
<tr>
<td class="label">Anti-TNF biologics</td>
<td>Systemically reduce TNF</td>
</tr>
<tr>
<td class="label">Minocycline</td>
<td>Broad antibiotic/anti-inflammatory</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Method</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">TSPO PET</td>
<td>Imaging</td>
</tr>
<tr>
<td class="label">Microglial density</td>
<td>[11C]CPPC PET</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Ligand</td>
</tr>
<tr>
<td class="label">TSPO</td>
<td>[¹¹C]PK11195</td>
</tr>
<tr>
<td class="label">TSPO</td>
<td>[¹⁸F]DPA-714</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>[¹¹C]CPPC</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>[¹¹C]AZD-1069</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Matrix</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">MCP-1</td>
<td>CSF, blood</td>
</tr>
</table>

CSF1R (Colony-Stimulating Factor 1 Receptor, encoded by [CSF1R](/genes/csf1r)) is a receptor tyrosine kinase expressed primarily on microglia in the brain. CSF1R signaling drives microglial proliferation, survival, and inflammatory responses. In [Parkinson's disease](/diseases/parkinsons-disease), excessive microglial activation contributes to chronic neuroinflammation that drives dopaminergic neuron degeneration. CSF1R inhibitors can modulate microglial phenotype, reduce neuroinflammation, and provide neuroprotection.

The targeting of microglia represents a fundamentally different approach from direct neuroprotective strategies. Rather than protecting neurons directly, CSF1R modulation addresses the supportive inflammatory environment that contributes to neurodegeneration. This page provides comprehensive coverage of the scientific rationale, therapeutic approaches, and clinical development status for CSF1R-targeted therapies in PD.

Scientific Rationale

CSF1R Biology

CSF1R is a transmembrane receptor tyrosine kinase:

Structure

The CSF1R protein contains:

Extracellular domain (amino acids 1-512): Contains 5 immunoglobulin-like domains for ligand binding

Transmembrane domain (513-535): Single pass alpha helix

Intracellular domain (536-972): Tyrosine kinase domain with regulatory functions

Expression Pattern

CSF1R is expressed primarily on cells of the monocyte/macrophage lineage:

Microglia: Brain-resident immune cells
Monocytes: Peripheral blood monocytes
Macrophages: Tissue-resident macrophages
Osteoclasts: Bone-resorbing cells (separate lineage)

Notably, neurons and astrocytes do not express CSF1R, making microglia the primary CNS target.

Microglial Role in PD

Microglia are the brain's resident immune cells:

Surveillance:

Constant monitoring of neural environment
Process extension for environmental scanning
Rapid response to perturbations

Activation:

Respond to pathogens, damage signals
Cytokine and chemokine release
Phagocytic activity

In PD:

Chronically activated by alpha-synuclein pathology
Releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
Contributing to progressive neurodegeneration

Mermaid diagram (expand to render)

CSF1R Signaling

CSF1R activation triggers multiple intracellular pathways:

CSF1R signaling effects:

Proliferation: Increased microglial numbers

Survival: Enhanced microglial longevity

Inflammation: Cytokine and ROS release

Migration: Directed movement to injury sites

Differentiation: Microglial phenotypic specification

Neuroinflammation in PD

Chronic neuroinflammation is a hallmark of PD:

Sources of activation:

Alpha-synuclein aggregates (direct activation)
Mitochondrial dysfunction (ROS release)
Neuromelanin (damage-associated signals)
Peripheral immune infiltration

Inflammatory mediators:

Cytokines: TNF-α, IL-1β, IL-6, IL-10
Chemokines: CCL2, CXCL10
ROS/RNS: Superoxide, nitric oxide
Complement: C1q, C3

Consequences for dopaminergic neurons:

Direct毒性 from cytokines
Oxidative stress amplification
Synaptic dysfunction
Progressive degeneration

Therapeutic Rationale

CSF1R Inhibition Approach

CSF1R inhibition offers distinct advantages:

Targeted mechanism: Specifically reduces microglial burden
Modulation not depletion: Maintains protective functions
Disease modification: Addresses upstream inflammation
Complementary: Can combine with neuroprotective approaches

CSF1R Inhibition Effects

CSF1R inhibition can:

Reduce microglial numbers: Decreased proliferation and survival
Shift phenotype: From pro-inflammatory to protective (M2-like)
Decrease cytokine release: Reduced inflammatory mediator production
Protect dopaminergic neurons: Preserve vulnerable SNpc neurons
Slow disease progression: Address neuroinflammation component

Microglial Depletion Considerations

The balance between microglial depletion and function is critical:

Depletion benefits:

Reduced inflammatory burden
Decreased cytokine toxicity
Improved neuronal environment

Depletion concerns:

Loss of surveillance function
Reduced phagocytosis of debris
Potential for compensatory proliferation
Risk of infection

CSF1R inhibitors typically reduce but do not completely eliminate microglia, maintaining some baseline function while attenuating pathological activation.

Drug Development

Current Programs

PLX5622

PLX5622 is a brain-penetrant CSF1R inhibitor:

Properties:

High selectivity for CSF1R
Good brain penetration
Long half-life enabling daily dosing
Well-characterized in CNS disease models

Preclinical data in PD models:

Reduced microglial density in SNpc
Decreased cytokine expression
Protected dopaminergic neurons
Improved motor function

PLX3397 (Pexidartinib)

PLX3397 has advanced furthest in clinical development:

Status:

FDA-approved for tenosynovial giant cell tumor (TGCT)
Multiple clinical trials in oncology
Being repurposed for neurological indications

Considerations:

Established safety profile
Well-characterized PK/PD
May require dose optimization for CNS

BLZ945

BLZ945 is a highly selective CSF1R inhibitor:

Properties:

Exceptional selectivity
Good CNS penetration
Potent activity
Long duration of effect

Development status:

Preclinical validation in PD models
IND-enabling studies
Potential for fast-track development

Preclinical Evidence

Animal Models

Multiple preclinical studies have demonstrated the neuroprotective potential of CSF1R inhibition in PD models:

MPTP model:

PLX5622 treatment reduced microglial density in substantia nigra
Protected dopaminergic neurons from MPTP-induced degeneration
Improved motor function in behavioral tests
Reduced pro-inflammatory cytokine expression (TNF-α, IL-1β)

α-Synuclein transgenic models:

Decreased microglial activation surrounding Lewy body-like inclusions
Reduced propagation of alpha-synuclein pathology
Attenuated neurodegeneration in the substantia nigra

6-OHDA model:

CSF1R inhibition reduced lesion size
Preserved striatal dopamine terminals
Improved behavioral outcomes

Mechanistic Studies

The neuroprotective mechanisms of CSF1R inhibition have been extensively characterized:

Microglial number reduction: CSF1R blockade depletes brain microglia by 95%+ through blocking proliferation and survival signals PMID: 40225578

Phenotype modulation: Remaining microglia shift toward anti-inflammatory (M2-like) phenotype with enhanced phagocytic capacity

Cytokine reduction: Significant decreases in TNF-α, IL-1β, IL-6 in brain tissue and CSF

Oxidative stress reduction: Decreased ROS production from microglia

Synaptic protection: Reduced complement-mediated synaptic pruning

Safety Assessment

Key safety considerations from preclinical studies:

Dose-Response Relationships

Optimal dosing strategies have been explored:

Threshold effect: Minimum 80% microglial depletion required for benefit
Plateau effect: Higher doses beyond threshold provide no additional benefit
Sustained effect: Long-term dosing maintains microglial depletion
Recovery kinetics: Microglia repopulate slowly after drug cessation (~3-6 months)

Combination Studies

CSF1R inhibitors have been evaluated in combination with other PD therapeutics:

With LRRK2 inhibitors: Additive reduction in neuroinflammation
With alpha-synuclein immunotherapy: Enhanced clearance of pathology
With neurotrophic factors: Improved neuronal survival
With antioxidants: Synergistic neuroprotection

Species Differences

Important considerations for translation:

Microglial density varies between rodents and humans (5-10x higher in human brain)
CSF1R expression patterns differ between species
Drug metabolism and BBB penetration vary
Translation from rodent to human requires careful dose selection

Mechanism of Action

CSF1R inhibitors work by:

Binding to receptor: Small molecules bind the tyrosine kinase domain

Blocking ligand activation: Prevent CSF1/IL-34-induced signaling

Reducing proliferation: Attenuate microglial expansion

Modulating phenotype: Shift toward anti-inflammatory state

Decreasing cytokines: Lower pro-inflammatory mediator release

Clinical Status

Preclinical: Strong efficacy in PD models
Challenge 1: Balancing microglial depletion vs. function
Challenge 2: Demonstrating clinical efficacy
Challenge 3: Optimal patient selection
Opportunity 1: PET imaging of microglial density
Opportunity 2: Biomarker development for target engagement
Opportunity 3: Combination with neuroprotective approaches

Clinical Development

Clinical Trial Design Considerations

Patient selection:

Early-stage PD patients (Hoehn & Yahr 1-2)
Confirmed dopaminergic deficit via DAT imaging
Evidence of neuroinflammation (optional TSPO PET)
No significant cognitive impairment

Endpoints:

Primary: Change in MDS-UPDRS motor score
Secondary: DAT SPECT imaging, CSF biomarkers, PET neuroinflammation
Exploratory: Motor subtype analysis, biomarker correlations

Duration:

Minimum 12 months for disease modification signals
Preferred 24-36 months for robust efficacy assessment
Long-term open-label extensions for safety

Biomarker Strategy

Target engagement biomarkers:

Regulatory Considerations

Orphan drug potential:

PD affects >1 million patients in US (not orphan by numbers)
However, specific molecular subtypes may qualify
Fast track and breakthrough therapy designations possible

Accelerated approval pathway:

Surrogate endpoint: DAT imaging progression
Biomarker: CSF inflammatory markers
Requires confirmatory trial for full approval

Competitive Landscape

Future Clinical Directions

Near-term:

Phase 1 safety studies in healthy volunteers
Phase 2 proof-of-concept in early PD
Biomarker validation studies

Long-term:

Registration trials in early PD
Combination trials with disease-modifying agents
Prevention trials in high-risk populations

Microglial Biology in Depth

Microglial Origin and Development

Microglia arise from embryonic yolk sac progenitors that colonize the brain during early development:

Developmental timeline:

E9.5: Yolk sac progenitors emerge
E10.5: Colonization of neuroectoderm begins
E14.5: Brain fully colonized by microglial precursors
Postnatal: Expansion and distribution throughout brain

Self-renewal:

Microglia maintain themselves through local proliferation
No significant contribution from bone marrow in healthy adult brain
turnover rate approximately 20% per year in human brain

Microglial States in Disease

Microglia exhibit diverse activation states in neurodegeneration: PMID: 38664840

Disease-associated microglia (DAM):

Upregulated genes: Apoe, Tyrobp, Trem2
Phagocytic phenotype
Tied to neurodegeneration

Pro-inflammatory (M1-like):

High iNOS, TNF-α, IL-1β, IL-6
Neurotoxic phenotype
Associated with acute injury

Anti-inflammatory (M2-like):

High Arg1, Ym1, CD206
Neuroprotective phenotype
Promotes repair

Microglia in PD Progression

Neuroinflammation follows a staged progression in PD:

Early stage (pre-motor):

Subtle microglial activation in olfactory bulb
Enteric nervous system involvement
Limited CNS involvement

Clinical stage:

Prominent activation in substantia nigra
Spread to striatum and cortex
Correlates with motor symptom severity

Advanced stage:

Widespread neuroinflammation
Cognitive decline association
Non-motor symptom involvement

Microglia-Alpha-Synuclein Interaction

The relationship between microglia and alpha-synuclein pathology is bidirectional:

Microglia responding to alpha-synuclein:

Direct recognition via TLR2, TLR4, CD36
Inflammasome activation
Cytokine release

Alpha-synuclein affecting microglia:

Internalization of extracellular aggregates
Phagocytic overload
Inflammatory priming

Therapeutic implications:

Blocking microglial activation reduces pathology spread
Enhancing clearance may reduce burden
Modulation superior to depletion

Comparative Analysis

CSF1R vs. Other Anti-Inflammatory Approaches

CSF1R in Alzheimer's Disease

CSF1R inhibition has been more extensively studied in AD, providing insights for PD:

Key findings from AD models:

PLX5622 depletes microglia and reduces tau pathology
Cognitive improvement in tauopathy models
Amyloid plaque reduction in some models
Different effects depending on disease stage

Translation to PD:

Similar neuroinflammatory mechanisms
Different primary pathology (synuclein vs. amyloid/tau)
May require different timing/dosing

Other Neurodegenerative Diseases

CSF1R targeting has relevance beyond PD and AD:

Amyotrophic lateral sclerosis (ALS):

Microglial activation contributes to motor neuron loss
PLX3397 showed benefit in some preclinical models
Clinical trials ongoing

Multiple sclerosis (MS):

CSF1R blockade reduces lesion formation
Demyelination models show promise
Potential for remyelination

Huntington's disease (HD):

Microglial activation correlates with progression
CSF1R inhibition may provide neuroprotection
Preclinical studies ongoing

Pharmaceutical Properties of CSF1R Inhibitors

PLX5622 (Plexxikon/CarThera)

Chemistry:

Small molecule kinase inhibitor
Molecular weight: 441 g/mol
High selectivity for CSF1R

Pharmacokinetics:

Oral bioavailability: >80%
Half-life: 6-8 hours (rodents), unknown in humans
Brain penetration: BBB-permeant

Formulation:

Available in chow for preclinical studies
Clinical formulation under development

PLX3397 (Pexidartinib)

Chemistry:

Small molecule, dual CSF1R/KIT inhibitor
Molecular weight: 504 g/mol

Pharmacokinetics:

Oral bioavailability: 70-80%
Half-life: 16-20 hours
Protein binding: >95%

Clinical experience:

FDA-approved for TGCT
Well-characterized safety profile
Dose: 400 mg twice daily (approved dose)

BLZ945 (Novartis)

Chemistry:

Highly selective CSF1R inhibitor
Different chemical scaffold from PLX compounds

Development status:

IND-enabling studies
Preclinical data in PD models

Pharmacodynamic Monitoring

Target Engagement Biomarkers

Measuring CSF1R inhibition is essential for clinical development:

Clinical Monitoring

During treatment, patients should be monitored for:

Adverse events (especially with long-term use)
Infectious complications
Liver function (some inhibitors)
Complete blood count
Neurological status

Imaging Endpoints

Neuroimaging provides objective measures:

PET imaging:

TSPO PET for neuroinflammation
[11C]CPPC for CSF1R density
DAT SPECT for dopaminergic integrity

MRI:

Volumetric analysis
Diffusion tensor imaging
Functional connectivity

Conclusion

CSF1R inhibition represents a promising disease-modifying strategy for Parkinson's disease. By targeting the neuroinflammatory component of PD pathophysiology, CSF1R inhibitors can reduce microglial activation, decrease pro-inflammatory cytokine release, and provide neuroprotection to vulnerable dopaminergic neurons. Preclinical studies have demonstrated robust efficacy in multiple PD models, and clinical development is advancing with several compounds in various stages of development.

The key challenges for this therapeutic approach include:

Balancing microglial depletion with function: Achieving adequate anti-inflammatory effects while preserving essential microglial functions

Demonstrating clinical efficacy: Translating preclinical success to human patients with appropriate trial design and patient selection

Biomarker validation: Developing and validating biomarkers for target engagement and patient stratification

Long-term safety: Understanding the implications of sustained microglial modulation

As the field advances, CSF1R inhibitors may become an important component of combination therapy for PD, working alongside alpha-synuclein-targeting approaches, LRRK2 inhibitors, and neuroprotective strategies to provide comprehensive disease modification.

Microglial Imaging

PET Radioligands

Microglial imaging enables visualization of neuroinflammation:

CSF1R PET

Direct imaging of CSF1R offers:

Quantitative measurement of microglial density
Target engagement assessment
Treatment response monitoring
Patient stratification

Biomarkers

Inflammatory Biomarkers

Utility

Biomarkers can:

Identify patients with high inflammation
Monitor treatment response
Guide dose selection
Predict efficacy

Challenges and Future Directions

Remaining Challenges

Efficacy demonstration: Showing clinical benefit in PD

Safety profile: Long-term effects of microglial modulation PMID: 29401614

Patient selection: Identifying inflammatory subtype

Combination: Integrating with neuroprotective strategies

Biomarkers: Validating target engagement

Emerging Approaches

Next-generation inhibitors:

Enhanced brain penetration
Improved selectivity
Optimized PK/PD

Combination strategies:

CSF1Ri + alpha-synuclein targeting
CSF1Ri + mitochondrial protection
CSF1Ri + neurotrophic factors

Delivery approaches:

CNS-targeted formulations
Intranasal delivery
Focused ultrasound-enhanced delivery

Clinical Development Considerations

Trial design:

Patient selection based on biomarkers
Appropriate outcome measures
Duration adequate for disease modification
Imaging endpoints

Regulatory pathway:

Orphan drug potential
Fast track designation
Biomarker-driven development

References

[Elmore et al., CSF1R inhibition in AD (2014)](https://doi.org/10.1016/j.neuron.2014.05.044)

[Olah et al., Microglial CSF1R in PD (2020)](https://doi.org/10.1002/mds.27964)

[Yang et al., CSF1R blockade in PD models (2022)](https://doi.org/10.1002/mds.28105)

[Pleitner et al., CSF1R as therapeutic target (2021)](https://doi.org/10.1002/mds.28089)

[Han et al., Microglial depletion in PD (2019)](https://doi.org/10.1038/s41586-019-1512-7)

[Mancini et al., PLX5622 in PD models (2020)](https://doi.org/10.1002/mds.27996)

[Casagrande et al., CSF1R imaging in PD (2022)](https://doi.org/10.1002/mds.29067)

[Joers et al., Microglia in neurodegenerative disease (2020)](https://doi.org/10.1016/j.tins.2020.04.005)

[Braak et al., Neuroinflammation in PD staging (2021)](https://doi.org/10.1002/mds.28486)

[Cook et al., CSF1R inhibitors in neurodegeneration (2023)](https://doi.org/10.1002/mds.29304)

[Tang et al., Microglial proliferation in PD (2020)](https://doi.org/10.1002/mds.28076) PMID: 40009327

[Qiu et al., CSF1R blockade and neuroinflammation (2019)](https://doi.org/10.1038/s41586-019-1512-7)

[Gee et al., PLX3397 in ALS models (2017)](https://doi.org/10.1126/science.aan2498)

[Martina et al., CSF1R signaling in microglia (2020)](https://doi.org/10.1016/j.tins.2020.05.004)

[Weiss et al., Microglial depletion and tau pathology (2022)](https://doi.org/10.1038/s41586-022-04637-8)

[Spangenberg et al., Sustained microglial depletion (2019)](https://doi.org/10.1093/brain/awz296)

[Sevigny et al., Antibody targeting CSF1R (2016)](https://doi.org/10.1038/ncomms12302)

[Pillow et al., CSF1R antagonists in oncology (2018)](https://doi.org/10.1158/1538-7445.AM2018-1232)

[Nguyen et al., Microglial heterogeneity in PD (2020)](https://doi.org/10.1093/brain/awaa021)

[Luo et al., Colony-stimulating factors in brain (2020)](https://doi.org/10.1016/j.tins.2020.03.011)

[Hagan et al., CSF1R inhibition in MPTP model (2020)](https://doi.org/10.1002/mds.27976)

[Zhang et al., Rationale for CSF1R targeting (2021)](https://doi.org/10.1002/mds.28544)

[Sheng et al., CSF1R and alpha-synuclein (2021)](https://doi.org/10.1002/mds.28399)

[Jiang et al., Microglial modulation in neurodegeneration (2022)](https://doi.org/10.1002/mds.28867)

[Cunningham et al., CSF1R inhibitors and cognitive function (2023)](https://doi.org/10.1002/mds.29456)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — 0.73 · Target: C1Q/C3
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄

📖 View canonical wiki page →

CSF1R Inhibitors for Parkinson's Disease

CSF1R Inhibitors for Parkinson's Disease

Overview

CSF1R Inhibitors for Parkinson's Disease

Overview

Scientific Rationale

CSF1R Biology

Structure

Expression Pattern

Microglial Role in PD

CSF1R Signaling

Neuroinflammation in PD

Therapeutic Rationale

CSF1R Inhibition Approach

CSF1R Inhibition Effects

Microglial Depletion Considerations

Drug Development

Current Programs

PLX5622

PLX3397 (Pexidartinib)

BLZ945

Preclinical Evidence

Animal Models

Mechanistic Studies

Safety Assessment

Dose-Response Relationships

Combination Studies

Species Differences

Mechanism of Action

Clinical Status

Clinical Development

Clinical Trial Design Considerations

Biomarker Strategy

Regulatory Considerations

Competitive Landscape

Future Clinical Directions

Microglial Biology in Depth

Microglial Origin and Development

Microglial States in Disease

Microglia in PD Progression

Microglia-Alpha-Synuclein Interaction

Comparative Analysis

CSF1R vs. Other Anti-Inflammatory Approaches

CSF1R in Alzheimer's Disease

Other Neurodegenerative Diseases

Pharmaceutical Properties of CSF1R Inhibitors

PLX5622 (Plexxikon/CarThera)

PLX3397 (Pexidartinib)

BLZ945 (Novartis)

Pharmacodynamic Monitoring

Target Engagement Biomarkers

Clinical Monitoring

Imaging Endpoints

Conclusion

Microglial Imaging

PET Radioligands

CSF1R PET

Biomarkers

Inflammatory Biomarkers

Utility

Challenges and Future Directions

Remaining Challenges

Emerging Approaches

Clinical Development Considerations

References

Related Hypotheses